Our Mission:Develop innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.The premier biotherapeutic targeting companyOur powerful AbiLeap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies of exquisite selectivity and affinity. The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics.We are dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need. 

Ability Biologics

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

Google Analytics

DNSSEC

Director, Lab Operations

Aldo Rozzo

Chief Executive Officer

Giles Day

Chief Operating Officer

Patrick Tremblay

Senior Scientist

Shivanthy Pathmanathan

Biotechnology Seed Stage Companies With Fewer Than 1000 Employees

Life Science Seed Stage Companies With Fewer Than 10 Employees

Startups Founded in 2023

Life Science Seed Stage Companies With Fewer Than 100 Employees

Ability biologics develops novel, tailored immune modifying biotherapeutics to address unmet medical requirements in cancer and autoimmune disease patients.

Amplitude Venture Capital

Seed Round - Ability biologics

Ville-marie

Quebec

Canada

North America

Ability biologics

Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension toward the Generation of Novel, Highly Targeted Immunomodulators

Ability Biologics Closes US $18M Seed Funding

Ability Biologics closes extended $18m seed funding round

Ability Biologics annonce la clôture de son financement de démarrage de 18 millions $ US pour la génération de nouveaux immunomodulateurs hautement ciblés

Ability Biologics: Cell Targeting Company Raises $18 Million In Seed Funding

Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension toward the Generation of Novel ...

Ability Biologics: Cell Targeting Company Raises $12 Million

A platform that uses AI and a large database of antigen-antibody interactions to generate fully human, multispecific antibodies with high selectivity and affinity.

Antibody-based therapeutics designed to modulate immune pathways, targeting cancer and autoimmune diseases with broad therapeutic applicability.

United States

Estonia

Europe

Hemgenix is a biotech company focused on gene therapies for rare diseases.

Hemgenix

Skysona is a biotech company specializing in gene therapies for rare diseases.

Skysona

Zynteglo is a biotech company known for its gene therapies for rare diseases.

Zynteglo

Zolgensma is a biotech company specializing in gene therapies for rare diseases.

Zolgensma

Luxturna is a biotech company focused on gene therapies for rare diseases.

Luxturna

Kite is a gene therapy company in Maryland working on innovative solutions for diseases and cancers.

Kite

Ability Bio is a biotechnology company focused on developing advanced therapies for rare and devastating diseases. Their approach combines cutting-edge science with a commitment to improving patient outcomes.

Ability Bio

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jun 20, 2024 11:33 AM	2f61bff3
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jun 20, 2024 1:30 PM	5d861998
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	2b067879
crunchbase profile	general	Nov 25, 2024 9:48 AM	d6de2173
li profile	general	Jun 20, 2024 11:33 AM	83a71b9d
translate crunchbase fundingrounds	general	Nov 25, 2024 2:07 PM	633a1f4f
peers	general
news basic	general	Jun 20, 2024 11:33 AM	51414a9b
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BIO:ABILITY

Ability Bio